Medivation, Inc.

525 Market Street
36th Floor
San Francisco
United States

Tel: 415-543-3470
Fax: 415-543-3411


Show articles for this employer

About Medivation, Inc.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.
For more information, please visit us at
October 1995
Founders: Clarence Patrick and David Hung
CEO and Co-founder: David Hung
CMO (Medical): Mohammad Hirmand
CFO: Jennifer Jarrett
Please click here for medivation job opportunities.
Please click here for clinical trial information.
All Productions

Currently, there are no jobs for this employer on BioSpace.

Browse jobs with BioSpace Featured Employers here.